{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:23:22Z","timestamp":1790461402121,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":5790,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1093\/annonc\/mdh103","type":"journal-article","created":{"date-parts":[[2004,3,3]],"date-time":"2004-03-03T19:13:19Z","timestamp":1078341199000},"page":"493-497","source":"Crossref","is-referenced-by-count":94,"title":["Gemcitabine and oxaliplatin (GEMOX) in patients withcisplatin-refractory germ cell tumors: a phase II study"],"prefix":"10.1016","volume":"15","author":[{"given":"D.","family":"Pectasides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pectasides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Farmakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Aravantinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Koumpou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kostopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mylonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Skarlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh103_bb0010","first-page":"2630","article-title":"Testicular cancer: an oncological success story","volume":"3","author":"Einhorn","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdh103_bb0015","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM199707243370406","article-title":"Testicular germ-cell cancer","volume":"337","author":"Bosl","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh103_bb0020","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1990.8.11.1777","article-title":"Treatment of testicular cancer: a new and improved model","volume":"8","author":"Einhorn","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh103_bb0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1200\/JCO.2001.19.1.81","article-title":"Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer","volume":"19","author":"Rick","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh103_bb0030","first-page":"353","article-title":"Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors","volume":"16","author":"Broun","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdh103_bb0035","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1200\/JCO.1996.14.4.1098","article-title":"High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity","volume":"14","author":"Motzer","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh103_bb0040","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1999.17.2.509","article-title":"Phase II trial of gemcitabine in refractory germ cell tumors","volume":"17","author":"Einhorn","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh103_bb0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/JCO.1999.17.2.512","article-title":"Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer","volume":"17","author":"Bokemeyer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh103_bb0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1005800520747","article-title":"Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines","volume":"15","author":"Dunn","year":"1997","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdh103_bb0055","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1200\/JCO.2002.08.050","article-title":"Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group","volume":"20","author":"Kollmannsberger","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh103_bb0060","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0021-9681(61)90060-1","article-title":"The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent","volume":"13","author":"Gehan","year":"1961","journal-title":"J Chronic Dis"},{"key":"10.1093\/annonc\/mdh103_bb0065","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1200\/JCO.2000.18.12.2413","article-title":"Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer","volume":"18","author":"Motzer","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh103_bb0070","first-page":"194a","article-title":"Phase II paclitaxel, ifosfamide and cisplatin as first-line chemotherapy in high risk germ cell tumours","volume":"20","author":"Cebotaru","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh103_bb0075","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1200\/JCO.2002.07.158","article-title":"Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group","volume":"20","author":"Hinton","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh103_bb0080","first-page":"194a","article-title":"Paclitaxel, cisplatin, gemcitabine (TPG) third line therapy in metastatic germ cell tumors (GCT) of the testis","volume":"20","author":"Pizzocaro","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr 1561","key":"10.1093\/annonc\/mdh103_bb0085","first-page":"22","article-title":"Combination chemotherapy with gemcitabine\/oxaliplatin in patients (pts) with relapsed or cisplatin-refractory germ-cell cancer (GCT)","volume":"389","author":"Bokemeyer","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh103_bb0090","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1200\/JCO.1994.12.11.2277","article-title":"Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors","volume":"12","author":"Motzer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh103_bb0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/oxfordjournals.annonc.a010473","article-title":"Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer","volume":"7","author":"Bokemeyer","year":"1996","journal-title":"Ann Oncol"},{"issue":"Abstr 1106","key":"10.1093\/annonc\/mdh103_bb0100","first-page":"17","article-title":"Weekly high-dose (HD) 5-fluorouracil (5-FU) and folinic acid (FA) with addition of oxaliplatin (LOHP) after documented progression under high-dose infusional 5-FU\/FA in patients (PTS) with advanced colorectal cancer (CRC): a preliminary report","volume":"287a","author":"Buechele","year":"1998","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419641499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419641499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/3\/493\/558573\/mdh103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T02:15:35Z","timestamp":1582251335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419641499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S0923753419641499"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh103","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}